A pooled analysis of data from three Phase III studies supports the observation that very low nadir testosterone achieved during monotherapy treatment with the LHRH agonist triptorelin is associated with improved OS and DSS in patients with advanced prostate cancer. The gene discussed is GNRH1; the disease is prostate carcinoma.